retatrutide investigational drug weight loss glp-1 reta Retatrutide, an experimental weight-loss drug, has not been approved by the FDA Retatrutide 2026: 28.7% Weight Loss

Traditional in-person care can add $200 to $400 per month in visit and lab fees

Patients should never increase their dose more rapidly than prescribed, even if they feel they are tolerating the current dose well

doi: 10.1111/apt.16550 40 SyedSBolandBSBourkeLTChenLAChurchillLDobesAet al

While higher-income individuals may manage to afford GLP-1s OOP, lower-income individuals who are more likely to be affected by obesity will face significant access barriers

United States import requirements Importing research peptides into the United States requires clear documentation establishing the material as research-use-only